scispace - formally typeset
Search or ask a question
Author

Kasim Dogan

Bio: Kasim Dogan is an academic researcher from Cumhuriyet University. The author has contributed to research in topics: Foreign body aspiration & Blood viscosity. The author has an hindex of 7, co-authored 25 publications receiving 220 citations.

Papers
More filters
Journal ArticleDOI
TL;DR: This recently recognized aspiration hazard can be minimized by using adhesive bands or snap fasteners, instead of pins, when wearing a turban, when worn by girls in Islamic countries.

55 citations

Journal ArticleDOI
TL;DR: It is found that TP aspiration has different characteristics and it deserves a special attention and is shown that the type and age groups of FBA varies according to cultural conditions.

39 citations

Journal ArticleDOI
TL;DR: TB ruptures in childhood regarding age, trauma presentation, injury localization and treatment options, and False negative bronchoscopic results increase when additional injuries accompany showed that these kinds of injuries threaten school age population as well.

23 citations

Journal Article
TL;DR: It is concluded that monofilament nylon sutureures diminish the risk of hypertrophic scarring, in comparison with absorbable sutures.
Abstract: We investigated cosmetic outcomes of the midline sternotomy incision. A randomized clinical trial was conducted in 60 patients who underwent surgery through a midline sternotomy incision. Patients were divided into groups A (n=30) and B (n=30). In addition, the incision line was also divided into 2 regions (upper and lower halves) in each group. In group A, the upper half of the skin was closed with absorbable 4-0 braided polyglycolic acid sutures (Sentesor®, Boz; Ankara, Turkey), and the lower half was closed with 4-0 nonabsorbable monofilamentous polypropylene suture (Monoplen®, Boz), and vice versa in group B. Scar width and height were measured and photographed at the 6th postoperative month. In both groups, the lower part of the incision showed inferior cosmetic results, regardless of the suture material (P < 0.05). On the other hand, the upper part of the incision in group A (the area of absorbable polyglycolic acid sutures) was significantly more hypertrophic. We conclude that monofilament nylon sutures diminish the risk of hypertrophic scarring, in comparison with absorbable sutures. In the lower half of the sternotomy scar, increased tension and relative mobility of the skin over the xiphoid process lead to inferior cosmetic results, regardless of the suture material used.

23 citations

Journal ArticleDOI
TL;DR: Among patients with AAA, the eNOS G894 T/T polymorphism and 894T allele frequency were associated with larger AAAs.
Abstract: Background: The genetic risk factors that contribute to the risk of developing abdominal aortic aneurysm (AAA) are poorly understood. We assessed the association of endothelial nitric oxide synthase (eNOS) gene polymorphism with AAA. Methods: eNOS gene polymorphism of 61 patients with AAA and 62 control participants were analyzed by polymerase chain reaction (PCR)-restriction technique. Results: eNOS G894 homozygote T/T genotype polymorphism and 894T allele frequency in patients with AAA were significantly higher than those of the control participants (P = .01, P = .03). Among patients with AAA, the eNOS G894 T/T polymorphism and 894T allele frequency were associated with larger AAAs. Conclusion: The current study, in a small group of participants, showed a relationship between eNOS G894T polymorphism and AAA.

13 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: It is reported that physical force regulates fibrosis through inflammatory FAK–ERK–MCP-1 pathways and that molecular strategies targeting FAK can effectively uncouple mechanical force from pathologic scar formation.
Abstract: Exuberant fibroproliferation is a common complication after injury for reasons that are not well understood. One key component of wound repair that is often overlooked is mechanical force, which regulates cell-matrix interactions through intracellular focal adhesion components, including focal adhesion kinase (FAK). Here we report that FAK is activated after cutaneous injury and that this process is potentiated by mechanical loading. Fibroblast-specific FAK knockout mice have substantially less inflammation and fibrosis than control mice in a model of hypertrophic scar formation. We show that FAK acts through extracellular-related kinase (ERK) to mechanically trigger the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as CCL2), a potent chemokine that is linked to human fibrotic disorders. Similarly, MCP-1 knockout mice form minimal scars, indicating that inflammatory chemokine pathways are a major mechanism by which FAK mechanotransduction induces fibrosis. Small-molecule inhibition of FAK blocks these effects in human cells and reduces scar formation in vivo through attenuated MCP-1 signaling and inflammatory cell recruitment. These findings collectively indicate that physical force regulates fibrosis through inflammatory FAK-ERK-MCP-1 pathways and that molecular strategies targeting FAK can effectively uncouple mechanical force from pathologic scar formation.

404 citations

Journal ArticleDOI
TL;DR: The increase in the number of randomized controlled trials over the past decade has greatly improved scar management, although these studies suffer from various limitations.
Abstract: Background:Previous reports on the treatment of hypertrophic scars and keloids have not described clear algorithms for multimodal therapies. This article presents an evidence-based review of previous articles and proposes algorithms for the treatment and prevention of hypertrophic scars and keloids.

294 citations

Journal ArticleDOI
01 Jun 2005-Chest
TL;DR: Investigation of the frequency of pulmonary problems in Behçet disease and immunopathologic findings indicate that the underlying pathogenesis is pulmonary vasculitis, which may result in thrombosis, infarction, hemorrhage, and PAA formation.

191 citations

Book ChapterDOI
TL;DR: Pharmacological stimulators of sGC may be beneficial in the treatment of a range of diseases, including systemic and pulmonary hypertension, heart failure, atherosclerosis, erectile dysfunction, and renal fibrosis.
Abstract: The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory properties of NO have been exploited for over a century in cardiovascular disease, but NO donor drugs and inhaled NO are associated with significant shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and non-specific effects such as post-translational modification of proteins. The development of pharmacological agents capable of directly stimulating the NO receptor, soluble guanylate cyclase (sGC), is therefore highly desirable. The benzylindazole compound YC-1 was the first sGC stimulator to be identified; this compound formed a lead structure for the development of optimized sGC stimulators with improved potency and specificity for sGC, including CFM-1571, BAY 41-2272, BAY 41-8543, and BAY 63-2521. In contrast to the NO- and haem-independent sGC activators such as BAY 58-2667, these compounds stimulate sGC activity independent of NO and also act in synergy with NO to produce anti-aggregatory, anti-proliferative, and vasodilatory effects. Recently, aryl-acrylamide compounds were identified independent of YC-1 as sGC stimulators; although structurally dissimilar to YC-1, they have a similar mode of action and promote smooth muscle relaxation. Pharmacological stimulators of sGC may be beneficial in the treatment of a range of diseases, including systemic and pulmonary hypertension, heart failure, atherosclerosis, erectile dysfunction, and renal fibrosis. An sGC stimulator, BAY 63-2521, is currently in clinical development as an oral therapy for patients with pulmonary hypertension. It has demonstrated efficacy in a proof-of-concept study, reducing pulmonary vascular resistance and increasing cardiac output from baseline. A full, phase 2 trial of BAY 63-2521 in pulmonary hypertension is underway.

190 citations